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This Cochrane Corner commentary will consider the findings of a recently published 
Cochrane Review by Jeffrey Walline and colleagues on ‘Interventions to slow 
progression of myopia in children’. (1) This is an update to a previous version of the 
review published by the same team in 2011. The review, which included 41 
randomised controlled trials recruiting 6772 children with myopia, investigated the 
comparative efficacy of 15 different optical and pharmacological interventions to slow 
the progression of myopia. The authors reported moderate-certainty evidence that 
antimuscarinic eye drops reduced the progression of myopia and attenuated axial 
elongation. Atropine showed the largest effect size, with an estimated 1.00 dioptre (D) 
reduction in myopia from baseline at 12 months compared with placebo. In terms of 
adverse effects, children receiving antimuscarinic eye drops were more likely to 
experience accommodative difficulties, photophobia and allergic reactions than 
participants receiving placebo. In one of the largest trials (2), 17% of children in the 
atropine group failed to complete the study compared to 5% in the placebo group. 
Studies investigating optical interventions such as multifocal spectacles or specialised 
contact lenses, showed that these had only a small benefit in slowing myopia (typically 
≤0.20D). 
Myopia is an important public health problem, affecting approximately 30% of the 
population globally. With current trends, the condition is predicted to affect 50% of the 
population by 2050. (3) Marked ethnic differences in age-specific prevalence exist, 
with myopia already reaching ‘epidemic’ proportions in certain parts of East and South 
East Asia. For example, in urban areas of countries in these regions, over up to 90% 
of children are myopic by the time they complete their high school education (4) Whilst 
a low degree of myopia is often regarded as a minor inconvenience, high myopia (≤ -
6.00D) is a major risk factor for a number of potentially blinding ocular pathologies, 
such as retinal detachment, myopic macular degeneration and glaucoma. Given the 
rapid increase in myopia prevalence and the associated risk of developing visually 
debilitating pathological myopia, there is a pressing need to develop and evaluate 
interventions to prevent myopia or slow its progression. Over the past 10 years, the 
number of published articles on ‘myopia control’ has increased exponentially (Figure 
1). . 
 
 
Figure 1 
The cumulative number of publications relating to myopia control published annually from 
1982 to 2019. The graph shows the number of articles retrieved from a PubMed search query 
using the term 'myopia control' from January 1982 to December 2019 
 
In such a rapidly moving field, it is particularly important that high quality systematic 
reviews are available to synthesise the accumulation of often conflicting research 
evidence to inform current practice. Given the large number of competing interventions 
for myopia control, there are considerable advantages in conducting a review that 
presents information on comparative effectiveness. A network meta-analysis (NMA) 
provides an analytical method for such a review. A NMA offers an advantage over a 
conventional pairwise meta-analysis in that it provides both direct comparisons of 
individual trials as well as indirect comparisons that were not directly evaluated in the 
included trials. A non-Cochrane NMA was published in 2016 (5) comparing 16 
separate interventions for myopia control in children. This review similarly concluded 
that the most effective interventions were pharmacological and specifically treatment 
with antimuscarinics such as atropine and pirenzepine.  
Atropine, whose name derives from Atropos, one of the three Fates in Greek 
mythology, who was said to determine a person’s moment of death, is an extremely 
potent poison that has been widely used in medicine since ancient times. (6) In the 
recent Cochrane update, evidence for the efficacy of atropine came from the findings 
of three RCTs that investigated the effect of higher doses of atropine (0.5% and 1.0%) 
versus placebo. (2,77,8)  Although demonstrating the effectiveness of these agents, 
based on their effect on spherical equivalent (SE) refractive error and axial length (AL), 
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there are a number of problems associated with the use of these higher concentrations 
of atropine including risk of side effects and a pronounced myopic ‘rebound’ following 
cessation of treatment. A follow up to the ‘Atropine for the Treatment of Childhood 
Myopia (ATOM)’ study (2), that provided the strongest evidence for the effectiveness 
of 1% atropine, investigated the use of three lower doses of atropine (0.5%, 0.1% and 
0.01%) (9). Whilst the ATOM 2 study was limited in not having a placebo group, it 
demonstrated that atropine 0.01% was the most effective of the three treatment arms 
in slowing myopia progression with fewer side effects. 
An Ophthalmic Technology Assessment by the American Academy of Ophthalmology 
published in 2017 (10), concluded that ‘Level I’ evidence supports the use of atropine 
to prevent myopic progression”. The review suggested that it may be preferable to use 
the lower 0.01% concentration due to the reduced likelihood of rebound and lower 
incidence of adverse effects. However, a number of clinical uncertainties were 
recognised, including the optimal time to initiate and discontinue therapy and whether 
the evidence arising almost exclusively from trials conducted in East and South East 
Asia are generalisable to other ethnic groups.  
Further evidence of the efficacy of lower doses of atropine comes from the recently 
published ‘Low-concentration Atropine for Myopia Progression (LAMP)’ study (11, 12), 
which investigated the effect of a range of low dose atropine concentrations (0.01%, 
0.025% and 0.05%) compared with placebo. All doses reduced myopia progression in 
a concentration-dependent manner, with 0.05% atropine being the most effective in 
controlling both SE myopic progression and AL elongation over a one-year period. All 
concentrations were well tolerated, with only a small reduction in amplitude of 
accommodation and pupil dilation with symptoms of photophobia reported in only 7.8% 
of participants using the 0.05% dose. 
The limited data on populations outside Asia may in part explain why atropine therapy 
is less widely prescribed in these regions. This is compounded by the lack of 
availability of a licensed low dose atropine preparation in many countries. There are a 
number of ongoing placebo-controlled trials of 0.01% atropine currently underway in 
the UK, Ireland and Western Australia. (13-15) These studies will provide valuable 
information on the efficacy and tolerability of low dose atropine in predominantly White 
populations. 
As new evidence emerges on interventions for myopia control, it is important that high 
quality systematic reviews are available to clinicians that encompass these new data. 
Cochrane Eyes and Vision have recently registered a NMA on interventions for myopia 
control in children. As well as including new evidence on pharmacological 
interventions (including combination therapy with other interventions (16-18)), this 
review will also incorporate newly published trials on novel optical interventions and 
include a brief economic commentary. For example, a dual-focus soft contact lens that 
integrates a central zone providing the distance correction with peripheral zones of 
myopic defocus, which has been shown to slow changes in SE refraction and AL in a 
trial in children aged 8 to 12 years. (19)  
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